Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
Spherix’s inaugural Patient Dynamix™: IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigation EXTON, PA – April 8, 2025 – Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid […]
Spherix Global Insights’ Tucker Hurtado Recognized as Luminary by Healthcare Businesswomen’s Association
Exton, PA, March 27, 2025 – Tucker Hurtado, Vice President of Product Planning at Spherix Global Insights, has been named a 2025 Luminary by the Healthcare Businesswomen’s Association (HBA). She will be recognized at the organization’s annual Woman of the Year celebration, taking place in Chicago on May 9, 2025. The HBA will proudly convene […]
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
As the IgAN market expands with the introduction of branded therapies, nephrologists express growing interest in the early-line potential of dual APRIL/BAFF inhibitors and atrasentan. [Exton, PA, March 26, 2025] – Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings from Spherix’s fifth annual […]
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting to adjust to the new treatment paradigm brought on by the entry of Humira biosimilars, sending sales of AbbVie’s mega-blockbuster down precipitously. But the […]
Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
Latest independent research from Spherix Global Insights highlights growing urgency to treat PNH with complement or factor inhibitors, shifting physician preferences, and the impact of biosimilar eculizumab entering the market. [Exton, PA, March 18, 2025] – Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in […]
Spherix Global Insights and the American Kidney Fund Announce Strategic Partnership and Inaugural Initiative to Elevate the Voice of Kidney Patients – Beginning with IgAN Patients
Formalizing a longstanding collaboration to unite patient advocacy and market expertise to drive advancements in kidney patient care. EXTON, PA., February 19, 2024 — Spherix Global Insights is proud to announce its partnership with the American Kidney Fund (AKF), marking a significant milestone in a collaboration aimed at advancing kidney care. This strategic alliance combines […]
Early Launch Metrics Indicate UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market
Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global Insights EXTON, PA, February 13, 2025 – UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis (PsA) market, with early indicators suggesting it could drive a […]
FDA Approval of Eli Lilly’s Omvoh for Crohn’s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists’ Brand Preferences Among the IL-23 Class, According to Spherix Global Insights
Despite greater physician pre-approval familiarity with Omvoh compared to J&J Innovative Medicine’s Tremfya, gastroenterologists favor Tremfya over Omvoh for Crohn’s disease. Exton, PA., January 29, 2025 – The FDA’s approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available for patients with this challenging […]
Humira, Cosentyx gaining favor as treatments for hidradenitis suppurativa, but more support for biologics needed: Spherix
The introduction of biologic therapies for hidradenitis suppurativa (HS) has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, according to Spherix Global Insights. A new white paper from the market research firm charts the impact of the introduction of biologics as a treatment for HS. First to earn […]
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights. EXTON, PA., November 1, 2024 — Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney diseases with critical unmet therapeutic needs, according to Spherix Global Insights […]
